Dr. Bill Maisel, deputy director for science at the FDA's Center for Devices & Radiological Health, tells medtech execs the agency is halfway through its review of the PMA process, which could result in some devices being removed from the high-risk category.
The FDA is about halfway through a retrospective study of its pre-market approval program, a review that could result in some devices being removed from the highest-risk category, according to Dr. Bill Maisel, deputy director for science at the FDA's Center for Devices & Radiological Health.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1uw4dXZ
Cap comentari:
Publica un comentari a l'entrada